key: cord-0749577-8dzd531d
authors: Jacobson, Mark A; Zakaria, Adam; Maung, Zaw; Hart, Colin; McCalmont, Tim; Fassett, Marlys; Amerson, Erin
title: Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees
date: 2021-06-04
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab518
sha: e1e3ce698a049ac27a1eeceabf0c7698e7e77950
doc_id: 749577
cord_uid: 8dzd531d

BACKGROUND: COVID-19 vaccines, primarily mRNA types, are administered to 2,000,000 individuals per day in the US under FDA emergency use authorization. METHODS: Observational cohort study of hospital workers who received their first SARS-CoV2 mRNA vaccination between December 14, 2020 and January 8, 2021, including cases reporting onset of an injection site reaction > 48 hours after administration of their first or second dose to an employee hotline. RESULTS: Thirteen female employees, who received mRNA-1273 SARS-CoV2 vaccine (Moderna) during the first three weeks of SARS-CoV2 vaccine rollout at San Francisco General Hospital, reported a pruritic rash at the injection site appearing 3-9 days after receiving their initial dose. Five had milder or similar reactions with earlier onset after the second dose. One additional female employee reported this delayed reaction only after the second dose. None of these 14 employees reported serious adverse events, such as anaphylaxis, or had symptoms severe enough to seek medical attention. These cases represented 1.1% of the 1,275 female employees who received their first mRNA-1273 dose, and 2.0% of the 557 who were 31-45 years old, during this initial vaccine rollout. None of 675 males initiating mRNA-1273 or 3,612 employees of either sex initiating BNT162b (Pfizer) vaccination during this period reported this delayed onset reaction. CONCLUSIONS: These results suggest that delayed-onset, injection-site pruritic rashes after mRNA-1273 SARS-CoV2 vaccine administration, lasting up to a week, occur commonly in females, do not lead to serious sequela, and should not deter receipt of the second vaccine dose.

M a n u s c r i p t 4 Introduction:

SARS-CoV2 vaccinations, primarily mRNA types, are administered to two million individuals per day in the United States to prevent COVID-19. 1 Due to the COVID-19 public health emergency, these vaccines were approved under an emergency use authorization (EUA) without long-term safety monitoring data. Continued monitoring of adverse events following vaccination will be critically important.

When employees at San Francisco General Hospital began receiving mRNA SARS-CoV2 vaccines, the Occupational Health Service (OHS) COVID-19 Emergency Response team established a vaccine hotline reporting system, and all employees vaccinated at the hospital were encouraged to call the hotline to report any subsequent severe or unusual adverse events. In early January 2021, this hotline began receiving calls from employees complaining of a large, red, itchy rash at the injection site of the mRNA-1273 vaccine (Moderna), which had appeared several days after vaccination and all initial local symptoms had resolved. While the public briefing document submitted to the FDA Vaccines and Related Biological Products Advisory Committee in support of Moderna's EUA application for mRNA-1273 on December 17, 2020, had mentioned local reactions persisting beyond 7 days in 3.7% of vaccine recipients and 1.3% of placebo recipients in the pivotal Phase 3 trial that led to EUA approval, it did not provide morphologic features, demographic data, time of onset, or the risk of such reactions after the second dose in subjects who reacted to the first. 2 Thus, to further characterize such delayed reactions reported to the OHS vaccine hotline, staff began obtaining a structured history and requesting photographs of skin abnormalities from these and subsequent employees who reported delayed onset symptoms at the injection site.

A c c e p t e d M a n u s c r i p t 5 The following report describes the clinical features, incidence, and demographic characteristics of this unique adverse event in a cohort of hospital employees.

Employees working at San Francisco General Hospital began receiving the BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) SARS-CoV2 mRNA vaccines on 12/14/2020 and 12/23/2020, respectively. Our analysis includes the cohort of all employees who received their initial BNT162b2 or mRNA-1273 vaccination at the hospital between December 14, 2020 and January 8, 2021. At the time of vaccination, staff administering the vaccine specifically advised employees that local symptoms were to be expected with onset during the first two days after vaccine administration and instructed them to call an Occupational Health Service (OHS) Vaccine Hotline if they had severe or unusual sides effects after vaccination. A case was defined as an employee who reported a cutaneous injection site reaction to OHS with the onset occurring at least two full days (48 hours) after vaccination.

OHS created a standard work algorithm for providers to systematically collect and document clinical information from any employee who reported onset of injection site symptoms that began two or more days after vaccine administration. This algorithm included asking the employee to send a photograph of the involved skin to OHS and notifying one of two hotline physicians (MAJ or ZM). In addition, a minimum 10 days after the second vaccine dose was administered to each case, they were asked to complete a questionnaire by telephone or secure email in order to validate and complete the clinical history that hotline providers had documented. These questionnaires were completed a median 21 (range 14-25) days after the second vaccine dose was administered. Size of the delayed injection site reaction was determined by one of the investigators (MAJ) from a photograph, if provided, or from the employee's own estimate.

A c c e p t e d M a n u s c r i p t 6 All cases provided informed consent, as required by the University of California San Francisco IRB, for any information in their medical record, including photographs, to be included in this report. One employee with this reaction also enrolled in a separate UCSF IRB-approved research protocol and underwent skin biopsy.

Using a database established by the hospital performance improvement team for vaccination recordkeeping, we obtained the total number of employees who received BNT162b2 or mRNA-1273 between 12/14/2020 and 1/8/2021, stratified within subgroups by vaccine received, self-identified sex, and the age groups of 18-30, 31-45, 46-65 and >65 years old.

Cumulative incidence of the delayed injection site reaction was calculated for the overall cohort and subgroups stratified by vaccine received (mRNA-1273 vs BNT162b), selfidentified gender (female vs male) and age group (18-30 vs 31-45 vs 46-65 vs >65 years old).

Rates of the reaction were compared between groups using the two-sided chi-square or Fisher's exact test. Rates of the reaction to second dose among employees who had the reaction to the first dose were compared between those who received the second dose in the same arm versus those who received it in the opposite arm using the two-sided Fisher's exact test. All analyses were performed using Stata Version 16.1 (Statacorp LLC), and p<0.05 was deemed significant for all tests. Among the subgroup of 557 female recipients age 31-45 years old, the incidence was 2.0%

[95% CI: 0.99% to 3.51%]. There were no reported delayed injection site reactions among the 675 male recipients of mRNA-1273 or the 3,612 employees who received BNT162b.

Rates of the delayed injection site reaction were significantly higher among recipients of mRNA-1273 compared to recipients of BNT162b (0.7% vs 0%; p<0.001) and among female compared to male recipients of mRNA-1273 (1.1% vs 0%; p=0.004). Among female recipients of mRNA-1273 there was a trend toward a higher rate among those 31-45 years old (18-30: 0.5% vs 31-45: 2.0% vs 46-65: 0.4% vs >65: 0%; p=0.10).

Thirteen employees, all females aged 28 to 55 years of age, reported a delayed injection site reaction, involving erythema and pruritus, which began two or more days after their initial mRNA-1273 vaccination. Figure 1A shows several examples of the morphology, and Table   1 provides individual case clinical details. The dimensions of involved skin ranged from 5 by 5 centimeters to 15 by 8 centimeters, appeared 3 to 9 (median 7) days after the first dose was administered, and lasted 2 to 7 (median 4) days. Pain or tenderness was reported by 7, A c c e p t e d M a n u s c r i p t 8 swelling or induration by 9, and lymphadenopathy by 2. Three employees reported using an over-the-counter medication to relieve pruritus symptoms (2 used an oral antihistamine and one a low-potency topical steroid).

Only 5 of these 13 individuals had a delayed reaction to the second dose, which started 2-3 days after injection and was less severe in 4 and of equal severity in 1. Reactions to the second dose were of similar duration to initial dose reactions (2-7 days). One additional female employee (number 12 in Table 1 ), who had no delayed reaction to the first mRNA-1273 injection, reported a mild reaction that began 2 days after the second injection.

Three of 5 employees who had this delayed reaction after the first dose and received their second injection in the same arm as the first had another delayed reaction after the second dose (cumulative incidence 0.60; 95% CI 0.17 to 1.03) compared to 2 of 7 who received their second injection in the opposite arm (cumulative incidence 0.29; 95% CI -0.04 to 0.62).

Thus, individuals who had this reaction after their first dose and received the second injection in the same arm as their first had 2.10 times the risk (95% CI 0.53-8.29) of another delayed reaction compared to those who received the second injection in the opposite arm, a nonsignificant trend (p=0.2763).

Demographic characteristics of the entire cohort and the 14 cases (age and gender) are provided in Table 2 . Race/ethnicity data was not available for the entire cohort. Potential medical co-factors that might affect the risk of having this reaction are listed in Table 1 . An atopic or allergic history (see Methods and Appendix for details) was reported by 5 cases. M a n u s c r i p t 9

Among the 12 participants of child-bearing age, only 3 reported using an oral or implantable hormonal contraceptive at the time of initial vaccination.

One case (number 14 in Table 1 ) had a skin biopsy done 4 days after the second mRNA-1273 dose was administered, while erythema and pruritus were still present. The punch biopsy specimen demonstrated a superficial and deep lymphohistiocytic infiltrate with scattered admixed interstitial neutrophils and eosinophils ( Figure 1B) . The overlying epidermis demonstrated very subtle spongiosis. A small segment of unaffected subcutis was included in the specimen. The histopathologic findings were most compatible with an urticarial hypersensitivity dermatitis.

In a cohort of 5,567 health care system employees, who received their first dose of an mRNA SARS-CoV2 vaccine to prevent COVID-19 over a 3 week period, shortly after the FDA granted EUAs for the administration of these vaccines, we report the incidence as well as clinical and demographic characteristics of a erythematous, pruritic delayed local injection site reaction to mRNA-1273 (Moderna) or BNT162b2 (Pfizer). We found such delayed skin reactions were reported by 1.1% of all female employees who received the mRNA-1273 and, when stratified by age, 2% of females 31-to 45 years old. No males who received mRNA-1273 and no employees of either sex who received BNT162b2 reported such reactions. The onset of these reactions occurred 3-9 (median 7) days after the first dose of mRNA-1273, consistent with two recent case series reports. 3, 4 Since an estimated 30 million American women in the 31-45 age group are eligible for vaccination to prevent COVID-19, 5 

A c c e p t e d M a n u s c r i p t 10 is imperative to accurately define the characteristics of these reactions and reassure the public that they resolve within a week and are not associated with medically significant adverse events.

A published subsequent analysis of over 14,000 mRNA-1273 recipients in the US Phase 3 trial reported delayed injection-site reactions in 0.8% of vaccine recipients after the first dose and 0.2% after the second dose, but few clinical details were provided. 6 A "delayed" reaction in this subsequent analysis was defined as an adverse event that began >8 days after injection. Given that our employees reported the onset of this local cutaneous reaction a median 7 days after receiving their first mRNA-1273 dose and 2 days after receiving their second dose, using this definition would have led to substantial under-reporting in our cohort. In fact, we suspect the incidence we observed of this reaction is actually an underestimate of true incidence because we relied on employees to self-report it to a hotline. Many health care professionals, in particular, may not have experienced these symptoms as alarming enough to warrant reporting.

Our OHS staff's initial concern after receiving the first reports of this vaccine reaction was whether employees might experience a more severe reaction to their second dose, a concern the general public might reasonably share. However, among the 13 employees who reported a delayed reaction after their first mRNA-1273 injection, only 5 reported a delayed reaction after their second; and 4 of these 5 rated the second reaction as less severe than the first. These findings corroborate those of Blumenthal et al, which found that only 8 of 12 individuals with this delayed reaction after the first dose of mRNA-1273 had a delayed skin reaction after the second dose, and all 8 reactions were mild. 3 Given widespread public concern about the safety of vaccines to prevent COVID-19 7 , it is important for public health agencies and providers to educate the public about the possibility of these delayed injection site reactions to mRNA-1273 and reassure them that they represent a benign process that does not preclude receiving the second vaccination dose. Since we observed a trend toward less risk of this reaction after the second dose, when it was given in the opposite arm from the first dose A c c e p t e d M a n u s c r i p t 11 (similar to the trend observed by Blumenthal et al 3 ) , it would be reasonable to suggest to individuals who have this reaction to mRNA-1273 after the first dose that they choose the opposite arm for their second dose. Future trials of mRNA vaccines that require more than one dose should also record and analyze whether local reactions differ after the second dose, based on whether it is administered in the same or opposite arm as the first dose.

The histopathology in our one case who underwent skin biopsy demonstrated findings compatible with a delayed-type hypersensitivity reaction. Similar findings were reported in a single skin biopsy from a patient with this delayed injection site reaction by Blumenthal et al. 3 Though delayed onset cutaneous reactions at the vaccine injection site are rare, such reactions to other vaccines have been reported and attributed to the presence of the preservatives thimersol, 2-phenoxyethanol, and aluminum as vaccine excipients. 8, 9 However, none of these are constituents of mRNA-1273 or BNT162b2. However, both the mRNA-1273 and BNT162b2 contain the vaccine excipient, polyethylene glycol, which is a rare cause of hypersensitivity with many skin-care products, medications, and foods and has been suggested as a potential allergen in mRNA vaccines. 10 More study is needed to determine the vaccine component driving these reactions, the immunologic mechanism, and a reason for the apparent differential incidence between these two mRNA SARS-CoV2 vaccines. One hypothesis to explore in attempting to explain this difference in delayed onset reactions between these two COVID019 mRNA vaccines is that the specific polyethylene glycol in mRNA-1273 (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 [PEG2000-DMG]) may cause more inflammation or be more immunogenic than the compound in BNT162b2 The exclusive occurrence that we observed in females is remarkable. In combining two previous case series 3, 4 with ours, 28 of 30 such cases (93%) were female (the registry-based report mentioned above does not mention the sex of those who had this reaction 11 ). Previous research has reported that women are at greater risk than men for adverse drug reactions. Hypotheses such as decreased body mass, sex-based differences in pharmacokinetics and pharmacodynamics, and gender-based differences in health information-seeking behaviors and self-image have been proposed. 12, 13 In conclusion, our data suggest that potential recipients of mRNA-1273 can be reassured that delayed injection-site reactions consistent with what we and others have observed are a common, benign, selflimited adverse event that should resolve within a week and do not appear to lead to serious sequela and that second mRNA-1273 doses are safe to administer to those who have the reaction after their first dose. In future Phase 3 vaccine trials to prevent COVID-19, safety reporting systems that capture the specific timing of adverse event onset might lead to earlier recognition and characterization of such delayed onset side effects. More research is needed to characterize the epidemiology, immunologic mechanism, prevention, and treatment of delayed injection site reactions to mRNAbased vaccines and why the delayed injection site reaction that we and others have observed has a predilection for females. Hotline calls were so helpful to employees and made this study possible. We are also very grateful to the employees who consented to participate in this study. 

None of the authors have any relation with a for-profit or not-for-profit third party whose interests may be affected by the content of this manuscript.

A c c e p t e d M a n u s c r i p t 14 

Daily COVID-19 vaccine doses administered. Our World in Data

Vaccines and Related Biological Products Advisory Committee

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

COVID Arm": A Reaction to the Moderna vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Kaiser Family Foundation. KFF COVID-19 Vaccine Monitor

Vaccine-associated hypersensitivity

Immune-mediated adverse reactions to vaccines

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study

Do women have more adverse drug reactions?

A c c e p t e d M a n u s c r i p t 16 A c c e p t e d M a n u s c r i p t